SAN DIEGO--(BUSINESS WIRE)--Metabasis Therapeutics, Inc. (Nasdaq:MBRX), a biopharmaceutical company focused on innovative therapies for metabolic diseases including hyperlipidemia and diabetes, today announced that it will hold a conference call to discuss the Company’s fourth quarter and year end financial results and provide a corporate update, including ongoing development activities for MB07811, the Company’s lead product candidate for hyperlipidemia.
